Skip to content
  • 2019 CATALOG
  • NEWSROOM
    • Latest News
    • Publications
    • Press Releases
    • Videos
    • Posters
    • Events
  • CONTACT
    • General Inquiries
    • Customer Support
    • Technical Support
    • Global Distributor Support
  • LabPMM
    • LabPMM, LLC (USA)
    • LabPMM, GmbH (Germany)
    • LabPMM, GK (Japan)
  • MY ACCOUNT
  • CART
Invivoscribe Logo Invivoscribe Logo Invivoscribe Logo
  • PRODUCTS
    • Products Overview

      Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

      EXPLORE PRODUCTS ⟶
    • Next-Generation Sequencing
      • CE-IVD
        • Illumina®
        • Thermo Fisher®
      • RUO
        • Illumina®
        • Thermo Fisher®
    • ABI Fluorescence Detection
      • CE-IVD
        • Clonality
        • FLT3
      • RUO
        • Clonality
        • FLT3
        • Translocations
      • Companion Diagnostics
    • Gel Detection
      • CE-IVD
        • Clonality
        • FLT3
        • Translocations
      • RUO
        • Clonality
        • FLT3
        • Translocations
    • Controls
      • Master Mix Controls
      • DNA Controls
      • RNA Controls
      • MRD Controls
    • Reagents
      • ASRs
      • Enzymes
      • Hi-Di Formamide
    • Companion Diagnostics (CDx)
    • 2019 Product Catalog
  • CLINICAL LAB SERVICES
    • Clinical Lab Services Overview

      The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

      EXPLORE SERVICES ⟶
    • NGS Cancer Panels
      • MyMRD
      • MyAML
      • MyHEME
    • MRD NGS Tests
      • Clonality
      • FLT3 ITD
      • NPM1
    • Targeted Genes
      • FLT3
      • NPM1
    • Clonality NGS Tests
      • SHM
      • IGH
      • IGK
      • TRG
      • TRB
    • Companion Diagnostic (CDx) Tests
      • CDx – USA
      • CDx – Germany
      • CDx – Japan
    • Custom Assays
    • 2019 Services Catalog
  • DISEASES
    • Lymphoid
      • Mature B-cell
      • Mature T-cell
    • Myeloid
      • Myelodysplastic Syndromes (MDS)
      • Acute Myeloid Leukemia (AML)
      • Myeloproliferative Neoplasms (MPNs)
    • Hematological Testing Menu

      Browse our comprehensive menu of product & testing services.

      EXPLORE MENU ⟶
  • PARTNERSHIPS
    • Partnerships Overview

      A proven strategy to accelerate drug approvals

      EXPLORE PARTNERSHIPS ⟶
    • Product Development

      Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

      EXPLORE ⟶
    • Manufacturing

      cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

      EXPLORE ⟶
    • LabPMM®

      Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

      EXPLORE ⟶
    • Global Regulatory Expertise

      Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

      EXPLORE ⟶
  • SCIENCE
    • Science Overview

      We take pride in expanding the science that bridges personalized medicine with quality healthcare.

      EXPLORE OUR SCIENCE ⟶
    • Personalized Medicine

      Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

      EXPLORE PERSONALIZED MEDICINE ⟶
  • PUBLICATIONS
    • Featured Publication

      March 21st, 2019
      Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

      VIEW PUBLICATION ⟶
    • Latest Publications

      August 25th, 2018
      A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

      VIEW PUBLICATION ⟶

      August 22nd, 2018
      Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

      VIEW PUBLICATION ⟶
      VIEW ALL PUBLICATIONS ⟶
  • COMPANY
    • Company
      • About Us
      • Leadership Team
      • Board of Directors
      • Global Distributors
      • Licensure and Certifications
      • Search Career Openings
    • Invivoscribe Locations
       
      Invivoscribe, Inc. (USA)
      San Diego, CA, US
      CONTACT US ⟶
       
      Invivoscribe, SARL (France)
      La Ciotat, France
      CONTACT US ⟶
       
      Invivoscribe Diagnostic Technologies,(Shanghai) Co.,Ltd.
      Shanghai, China
      CONTACT US ⟶
    • LabPMM Locations
       
      LabPMM, LLC (USA)
      San Diego, CA, US
      CONTACT US ⟶
       
      LabPMM, GmbH (Germany)
      Martinsried, Germany
      CONTACT US ⟶
       
      LabPMM, GK (Japan)
      Kanagawa 210-0821, Japan
      CONTACT US ⟶
    • Support
       
      Invivoscribe, Inc. (USA)
      CONTACT US ⟶
       
      Invivoscribe, SARL (France)
      CONTACT US ⟶
       
      Invivoscribe Diagnostic Technologies,(Shanghai) Co.,Ltd.
      CONTACT US ⟶
       
      LabPMM, LLC (USA)
      CONTACT US ⟶
       
      LabPMM, GmbH (Germany)
      CONTACT US ⟶
       
      LabPMM, GK (Japan)
      CONTACT US ⟶
SEARCH & FILTER
  • Territory

  • Detection

  • Regulatory Classification

  • Locus Target

  • Application

  • Product Type

  • Box Type

  • Design

  • Size

  • Reset Filter
  • Territory

  • Detection

  • Regulatory Classification

  • Locus Target

  • Application

  • Product Type

  • Box Type

  • Design

  • Size

  • Reset Filter
    Home/Posts/Featured Publications, Publications/Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms
    Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms
    admin2019-07-31T18:47:58+00:00March 21st, 2019|Categories: Featured Publications, Publications|

    Share This Post

    FacebookTwitterLinkedIn

    INVIVOSCRIBE

     
    Invivoscribe, Inc. (USA)
    San Diego, CA, US
    CONTACT US ⟶
     
    Invivoscribe, SARL (France)
    La Ciotat, France
    CONTACT US ⟶
     
    Invivoscribe Diagnostic Technologies,(Shanghai) Co.,Ltd.
    Shanghai, China
    CONTACT US ⟶

    LabPMM

     
    LabPMM, LLC (USA)
    San Diego, CA, US
    CONTACT US ⟶
     
    LabPMM, GmbH (Germany)
    Martinsried, Germany
    CONTACT US ⟶
     
    LabPMM, GK (Japan)
    Kanagawa 210-0821, Japan
    CONTACT US ⟶

    PRIVACY/TERMS & CONDITIONS

    Terms and Conditions
    Web Privacy Policy
    Privacy Shield Policy
    Licensure and Certifications
    Global Distributors

    CONNECT

    © 2018 -    |   Invivoscribe, Inc. |   All Rights Reserved
    • PRODUCTS
      • Products Overview
      • Next-Generation Sequencing
        • CE-IVD
          • Illumina®
          • Thermo Fisher®
        • RUO
          • Illumina®
          • Thermo Fisher®
      • ABI Fluorescence Detection
        • CE-IVD
          • Clonality
          • FLT3
        • RUO
          • Clonality
          • FLT3
          • Translocations
        • Companion Diagnostics
      • Gel Detection
        • CE-IVD
          • Clonality
          • FLT3
          • Translocations
        • RUO
          • Clonality
          • FLT3
          • Translocations
      • Controls
        • Master Mix Controls
        • DNA Controls
        • RNA Controls
        • MRD Controls
      • Reagents
        • ASRs
        • Enzymes
        • Hi-Di Formamide
      • Companion Diagnostics (CDx)
      • 2019 Product Catalog
    • CLINICAL LAB SERVICES
      • Clinical Lab Services Overview
      • NGS Cancer Panels
        • MyMRD
        • MyAML
        • MyHEME
      • MRD NGS Tests
        • Clonality
        • FLT3 ITD
        • NPM1
      • Targeted Genes
        • FLT3
        • NPM1
      • Clonality NGS Tests
        • SHM
        • IGH
        • IGK
        • TRG
        • TRB
      • Companion Diagnostic (CDx) Tests
        • CDx – USA
        • CDx – Germany
        • CDx – Japan
      • Custom Assays
      • 2019 Services Catalog
    • DISEASES
      • Lymphoid
        • Mature B-cell
        • Mature T-cell
      • Myeloid
        • Myelodysplastic Syndromes (MDS)
        • Acute Myeloid Leukemia (AML)
        • Myeloproliferative Neoplasms (MPNs)
      • Hematological Testing Menu
    • PARTNERSHIPS
      • Partnerships Overview
      • Product Development
      • Manufacturing
      • LabPMM®
      • Global Regulatory Expertise
    • SCIENCE
      • Science Overview
      • Personalized Medicine
    • PUBLICATIONS
      • Featured Publication
      • Latest Publications
    • NEWSROOM
      • Latest News
      • Publications
      • Press Releases
      • Videos
      • Posters
      • Events
    • COMPANY
      • Company
        • About Us
        • Leadership Team
        • Board of Directors
        • Newsroom
        • Global Distributors
        • Licensure and Certifications
        • Search Career Openings
      • Invivoscribe Locations
        • Invivoscribe, Inc. (USA)
        • Invivoscribe, SARL (France)
        • Invivoscribe Diagnostic Technologies (Shanghai) Co., Ltd.
      • LabPMM Locations
        • LabPMM, LLC (USA)
        • LabPMM, GmbH (Germany)
        • LabPMM, GK (Japan)
      • Support
    LATEST NEWS

    European Commission Approves Astellas’ XOSPATA™ for Patients ⟶

    CONNECT